Inspire Investing LLC Purchases Shares of 22,979 Enovis Corporation $ENOV

Inspire Investing LLC purchased a new position in shares of Enovis Corporation (NYSE:ENOV) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,979 shares of the company’s stock, valued at approximately $523,000.

A number of other hedge funds have also recently made changes to their positions in the business. California State Teachers Retirement System grew its holdings in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after purchasing an additional 621 shares during the last quarter. MGO One Seven LLC lifted its stake in Enovis by 9.4% in the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after purchasing an additional 650 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Empowered Funds LLC boosted its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares during the period. Finally, Inscription Capital LLC boosted its position in Enovis by 9.4% during the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after buying an additional 1,016 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ENOV. Wells Fargo & Company decreased their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. William Blair assumed coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Zacks Research downgraded Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Finally, Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Performance

Enovis stock opened at $22.60 on Friday. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The firm has a 50-day moving average of $23.25 and a 200-day moving average of $23.87. The firm has a market cap of $1.30 billion, a P/E ratio of -1.14 and a beta of 1.39. Enovis Corporation has a 1-year low of $19.14 and a 1-year high of $36.82.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the previous year, the business earned $0.81 EPS. Enovis’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 3.12 EPS for the current year.

Insiders Place Their Bets

In related news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders purchased 4,200 shares of company stock worth $92,084. 2.90% of the stock is owned by company insiders.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.